FDA, Plavix-Makers Will Study the Drug’s Efficacy

February 6, 2009
Bristol-Myers Squibb and Sanofi-Aventis will conduct genetic and drug-interaction studies to determine why their blockbuster cardiovascular drug Plavix works better in some patients than in others, the FDA says in a recent MedWatch report. The companies could take several months to complete and analyze the new studies on how genetic factors and other drugs may affect the body’s ability to metabolize Plavix (clopidogrel bisulfate).
Washington Drug Letter